GraniteShares YieldBOOST Biotech ETF
$20.28−0.34 (−1.63%)
- Expense ratio
- 1.07%
- Fund size
- $1M
- 1Y return
- —
- Yield · Last 12 months
- Data unavailable
- Volume · 30D
- 0M sh
- NAV per share
- $20.43
- 52W range
The ETF.net BIOY Grade
Score 20 of 100 sits in the F band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E. A structural cap ceilings this fund at 40, so B and A are out of reach.
Cost
What you pay to own it — the expense ratio plus trading frictions, ranked within its category.FScore 5Category rankMission
How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.Not scoredRisk
How violently it can move — volatility, drawdown depth, and downside capture versus its category.BScore 57Category rankTradability
How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.FScore 14Category rankHoldings
What it actually owns — the quality, breadth, and concentration of the underlying portfolio.Not scoredDurability
Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.DScore 27Category rank
Our read on BIOY
FMost sector income funds sell calls on the sector itself. BIOY goes one level up: it sells puts on a 3x leveraged biotech ETF, mining the fat premiums that come with one of the market's twitchiest wrappers, and pays cash out weekly.
The Fund seeks to generate three times the income from selling options on the S&P Biotechnology Select Industry Index through options on leveraged ETFs, while also seeking exposure to the leveraged ETF’s performance subject to a cap.
Why people hold it
- The income engine is the whole point: writing puts on a 3x biotech ETF harvests the elevated implied volatility leveraged funds throw off, with distributions paid weekly.graniteshares.com
- It doesn't hold the leveraged biotech ETF. Exposure runs through the options book, aiming at 3x the income from selling options on the S&P Biotechnology Select Industry Index.graniteshares.com
- One ticker replaces a standing options program: strike selection, short-dated expiries and the weekly roll are handled inside a 1940 Act fund.graniteshares.com
- GraniteShares discloses that payouts can include return of capital, so the character of each distribution is documented rather than left to guesswork.graniteshares.com
Worth knowing
- At 1.07%, the fee runs about triple the 0.35% median of its sector-overlay peer group, where the State Street Premium Income funds (XLVI, XLUI) sit.
- The payoff shape is lopsided: upside is capped by design while the put book absorbs the downside of a 3x daily biotech ETF, a tool built for one-day moves.
- Small and thinly traded, and it only started trading in 2026, so there is little history behind it and execution costs deserve attention.
BIOY Holdings
- Other
- —
- 101%
- US Dollars
BIOY Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | BIOY |
|---|---|
| Year to date | — |
| 1 month | +2.1% |
| 3 months | +4.2% |
| 1 year | — |
| 3 years | — |
| 5 years | — |
| 10 years | — |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | BIOY |
|---|---|---|
| 2026 YTD | +3.7% |
BIOY in the news
ETF.net Research hasn’t filed on BIOY yet — coverage lands here as it’s written.
BIOY Dividends
- $0.23 per share
- Weekly
Distribution data unavailable.
Distribution history
| Ex-date | Pay date | Amount per share |
|---|---|---|
| Sep 18, 2026 | Sep 22, 2026 | $0.23 |
| Sep 11, 2026 | Sep 15, 2026 | $0.25 |
| Sep 4, 2026 | Sep 9, 2026 | $0.25 |
| Aug 28, 2026 | Sep 1, 2026 | $0.25 |
| Aug 21, 2026 | Aug 25, 2026 | $0.25 |
| Aug 14, 2026 | Aug 18, 2026 | $0.25 |
| Aug 7, 2026 | Aug 11, 2026 | $0.24 |
| Jul 31, 2026 | Aug 4, 2026 | $0.24 |
| Jul 24, 2026 | Jul 28, 2026 | $0.25 |
| Jul 17, 2026 | Jul 21, 2026 | $0.25 |
| Jul 10, 2026 | Jul 14, 2026 | $0.26 |
| Jul 2, 2026 | Jul 7, 2026 | $0.26 |
BIOY Risk
- —
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- —
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- —
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 0.56
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
BIOY Cost
- The middle half of Sector Option Income funds
- Median 0.47%
19 of the 22 Sector Option Income funds charge less.